Angiozyme: Phase I/II

In a U.S. Phase I/II trial, subcutaneous injections of up to 300 mg/m 2/day of Angiozyme for 29 days were well tolerated in 31 patients with progressive cancer. A total of 17 evaluable patients had stable disease ranging from 1-8 months, with 4 patients still receiving therapy. A total of 2 patients had a minor clinical response. RZYM said that the compound showed bioavailability supporting daily subcutaneous administration. Data were presented at the New Drugs in Cancer Therapy meeting in Amsterdam. ...